Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CADUET vs ELETRIPTAN HYDROBROMIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Amlodipine: Dihydropyridine calcium channel blocker that inhibits calcium ion influx across cardiac and vascular smooth muscle cell membranes, causing vasodilation and reduced peripheral vascular resistance. Atorvastatin: HMG-Co A reductase inhibitor that competitively inhibits the conversion of HMG-Co A to mevalonate, reducing cholesterol synthesis in the liver.
Selective 5-HT1B/1D receptor agonist; causes vasoconstriction of cranial arteries and inhibition of trigeminal nerve transmission.
Hypertension,Coronary artery disease,Hyperlipidemia (as adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels, and to increase HDL-C),Prevention of cardiovascular events in patients with multiple risk factors
Acute treatment of migraine with or without aura in adults
CADUET (amlodipine/atorvastatin) is available as tablets of 2.5/10, 2.5/20, 2.5/40, 5/10, 5/20, 5/40, 5/80, 10/10, 10/20, 10/40, and 10/80 mg amlodipine/atorvastatin. Initial dose depends on current antihypertensive and lipid-lowering therapy. Usual starting dose is 5/10 mg orally once daily; titrate at intervals of 2-4 weeks based on blood pressure and LDL-C goals. Maximum daily dose: amlodipine 10 mg; atorvastatin 80 mg.
40 mg orally once, may repeat after 2 hours if headache recurs; maximum 80 mg/day.
Amlodipine: terminal half-life 30-50 h (enables once-daily dosing). Atorvastatin: terminal half-life ~14 h, but active metabolites (ortho- and para-hydroxy atorvastatin) have half-life 20-30 h; clinically, pharmacodynamic half-life (HMG-Co A reductase inhibition) is ~20-30 h.
Terminal elimination half-life is approximately 4-5 hours in healthy adults. In patients with hepatic impairment, half-life may be prolonged up to 8 hours. The half-life supports a clinical duration suitable for acute migraine treatment, with no accumulation with single doses.
Amlodipine: Extensively metabolized in the liver via CYP3A4 to inactive metabolites. Atorvastatin: Metabolized in the liver primarily by CYP3A4 to active ortho- and para-hydroxylated metabolites.
Primarily metabolized by CYP3A4; also minor contribution from CYP2C9, CYP2C19, and CYP2D6.
Amlodipine: 60% renal (metabolites), 20-25% biliary/fecal. Atorvastatin: 1% renal (unchanged), 90% biliary/fecal (≥70% as metabolites).
Approximately 90% of the dose is eliminated in feces, with less than 10% recovered in urine. Renal excretion accounts for about 9% of total clearance, primarily as unchanged drug. Biliary/fecal elimination is the major route.
Amlodipine: ~93% bound to plasma proteins. Atorvastatin: ≥98% bound to plasma proteins (mainly albumin).
Approximately 85% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Amlodipine: Vd ~21 L/kg (large, indicating extensive tissue distribution). Atorvastatin: Vd ~6.2 L/kg (moderately large, suggesting distribution into tissues).
Volume of distribution is approximately 1.4 L/kg (range 1.0-2.0 L/kg), indicating extensive distribution into tissues beyond total body water.
Oral: amlodipine 64-90%; atorvastatin ~14% (low due to first-pass metabolism); food reduces rate but not extent of absorption.
Oral bioavailability is approximately 50% (range 30-70% due to first-pass metabolism) for the tablet formulation. Absolute bioavailability is moderate due to presystemic clearance.
No dosage adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). For severe renal impairment (Cr Cl <30 m L/min), use atorvastatin with caution; maximum atorvastatin dose is 20 mg daily. Amlodipine is not dialyzable.
No dose adjustment required for mild to moderate renal impairment; contraindicated in severe renal impairment (Cr Cl <10 m L/min).
Contraindicated in active liver disease or unexplained persistent elevations of serum transaminases. For Child-Pugh Class A or B hepatic impairment: atorvastatin dose should be reduced; maximum atorvastatin dose is 20 mg daily. Amlodipine clearance is decreased; initial amlodipine dose should be 2.5 mg daily. No data for Child-Pugh Class C; use contraindicated.
Contraindicated in severe hepatic impairment (Child-Pugh C); no adjustment for mild to moderate impairment.
Not recommended for pediatric patients. Safety and efficacy in children <10 years have not been established. For patients 10-17 years with heterozygous familial hypercholesterolemia, atorvastatin monotherapy is used; CADUET is not indicated.
Not established; safety and efficacy in patients <18 years not studied.
Elderly patients (≥65 years) may have increased sensitivity to amlodipine; start at the lower end of dosing range (2.5 mg amlodipine component). Atorvastatin dose adjustment not required based on age alone. Monitor for hypotension and other adverse effects.
Use with caution due to potential decreased hepatic/renal function; consider lower starting dose (20 mg).
HMG-Co A reductase inhibitors (statins) can cause fetal harm; use in pregnant women is contraindicated. Caduet contains atorvastatin; therefore, it is contraindicated in pregnant women.
No FDA boxed warning.
Myopathy/Rhabdomyolysis: Risk increased with higher doses, age >65, renal impairment, hypothyroidism, and concurrent use of CYP3A4 inhibitors or other drugs that cause myopathy.,Hepatic effects: Elevated liver enzymes; perform liver function tests before initiation and as clinically indicated.,Fetal toxicity: May cause fetal harm; advise females of reproductive age to use effective contraception.,Peripheral edema: More common with higher doses of amlodipine, especially in females.,Hypotension: In patients with severe aortic stenosis.
Coronary artery vasospasm and ischemic heart disease,Cerebrovascular events (stroke, transient ischemic attack),Life-threatening serotonin syndrome (especially with SSRIs/SNRIs),Hypertensive crisis in patients with uncontrolled hypertension,Risk of myocardial ischemia in patients with risk factors
Active liver disease or unexplained persistent elevations of hepatic transaminases,Pregnancy,Breastfeeding (due to potential for serious adverse reactions in nursing infants),Hypersensitivity to amlodipine, atorvastatin, or any component of the formulation
History of ischemic heart disease or coronary artery vasospasm,Uncontrolled hypertension,Hemiplegic or basilar migraine,Use within 24 hours of another triptan or ergotamine,Concurrent use of MAO inhibitors or within 2 weeks of discontinuation,Severe hepatic impairment (Child-Pugh C)
Avoid grapefruit and grapefruit juice as they increase atorvastatin plasma concentrations and risk of adverse effects. No significant food interactions with amlodipine.
Grapefruit and grapefruit juice should be avoided as they inhibit CYP3A4, increasing eletriptan exposure and risk of adverse effects. No other significant food interactions reported.
FDA Pregnancy Category X. Amlodipine: No evidence of teratogenicity in animal studies, but limited human data; atorvastatin: contraindicated in pregnancy as HMG-Co A reductase inhibitors are associated with fetal abnormalities, including skeletal and CNS defects. First trimester: Atorvastatin is contraindicated; risk of congenital anomalies. Second/third trimester: Avoid exposure; potential for fetal toxicity. Effective contraception required for women of childbearing potential.
Limited human data; animal studies show no teratogenicity at clinically relevant doses. First trimester: risk cannot be excluded; second/third trimester: no known increased risk. Avoid in third trimester due to possible uterine atony or decreased placental perfusion.
Excreted in human milk: Amlodipine: present in low levels (M/P ratio approximately 1.0); atorvastatin: unknown. Due to potential for serious adverse reactions in nursing infants (e.g., skeletal muscle toxicity from statins), breastfeeding is contraindicated during therapy. Alternative agents preferred.
Excreted into breast milk in low amounts (M/P ratio unknown). Relative infant dose estimated at <1% of maternal weight-adjusted dose. Considered compatible with breastfeeding; monitor infant for irritability and sleep disturbance.
Contraindicated during pregnancy; therefore, no dosing adjustments recommended. Discontinue therapy immediately if pregnancy is suspected or confirmed. Pharmacokinetic changes during pregnancy may alter drug metabolism, but no dose adjustments are justified due to teratogenic risk.
No specific dose adjustment recommended; pharmacokinetic changes in pregnancy (increased volume of distribution, clearance) may reduce efficacy, but standard dosing remains safe. Consider lowest effective dose.
CADUET is a fixed-dose combination of amlodipine (a calcium channel blocker) and atorvastatin (a statin) used for hypertension and dyslipidemia. Avoid concomitant use with strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole) due to increased statin exposure and risk of myopathy. Monitor liver enzymes before and during therapy, and for muscle symptoms. Use with caution in patients with severe renal impairment. Avoid grapefruit juice as it increases atorvastatin levels.
Eletriptan has higher lipophilicity and longer half-life than sumatriptan, potentially offering better CNS penetration and sustained efficacy. Contraindicated within 24 hours of other triptans or ergotamines. Avoid in patients with severe hepatic impairment (Child-Pugh C) as metabolism is CYP3A4-dependent. Maximum single dose 40 mg; may repeat after 2 hours if no response, but do not exceed 80 mg/day. Onset typically within 30 minutes; if first dose fails, consider alternative therapy for subsequent attacks.
Take this medication once daily at the same time, with or without food.,Avoid grapefruit and grapefruit juice while taking this medication.,Report unexplained muscle pain, tenderness, or weakness, especially if accompanied by fever or malaise.,Notify your doctor if you become pregnant, plan to become pregnant, or are breastfeeding.,Do not stop taking this medication without consulting your doctor, even if you feel well.
Take at the first sign of migraine headache, not for prevention.,Do not take more than 80 mg in 24 hours; wait at least 2 hours between doses.,Avoid taking within 24 hours of other triptans or ergotamine medications.,Report chest pain, palpitations, or shortness of breath immediately.,Do not use if you have uncontrolled high blood pressure, coronary artery disease, or history of stroke.,Grapefruit juice may increase drug levels; avoid consumption during treatment.,Swallow tablet whole; do not crush or chew.
No interactions on record
"Eletriptan, a 5-HT1B/1D receptor agonist used for migraine, and ondansetron, a 5-HT3 receptor antagonist antiemetic, both increase serotonergic activity via different mechanisms. Concurrent use may lead to excessive serotonin accumulation, potentially triggering serotonin syndrome, characterized by neuromuscular excitation, autonomic instability, and altered mental status. While the interaction is mechanistically plausible, clinical reports are rare, and caution is advised particularly in patients on multiple serotonergic agents."
"Concomitant use of eletriptan, a 5-HT1B/1D receptor agonist, with maprotiline, a tetracyclic antidepressant that inhibits serotonin reuptake, may result in additive serotonergic effects. This increases the risk of serotonin syndrome, a potentially life-threatening condition characterized by neuromuscular excitation, autonomic instability, and altered mental status. Patients combining these agents require close monitoring for symptoms such as hyperthermia, clonus, hyperreflexia, and agitation."
"Concomitant use of eletriptan and almotriptan, both triptan-class 5-HT1B/1D receptor agonists, increases the risk of serotonin syndrome and additive vasoconstriction, including coronary vasospasm. Excessive serotonergic activity may lead to neuromuscular excitation, autonomic instability, and altered mental status, while additive arterial vasoconstriction can precipitate severe hypertension or ischemic events, especially in patients with cardiovascular risk factors."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CADUET vs ELETRIPTAN HYDROBROMIDE, answered by our medical review team.
CADUET is a Calcium Channel Blocker + HMG-CoA Reductase Inhibitor that works by Amlodipine: Dihydropyridine calcium channel blocker that inhibits calcium ion influx across cardiac and vascular smooth muscle cell membranes, causing vasodilation and reduced peripheral vascular resistance. Atorvastatin: HMG-Co A reductase inhibitor that competitively inhibits the conversion of HMG-Co A to mevalonate, reducing cholesterol synthesis in the liver.. ELETRIPTAN HYDROBROMIDE is a 5-HT1 Agonist that works by Selective 5-HT1B/1D receptor agonist; causes vasoconstriction of cranial arteries and inhibition of trigeminal nerve transmission.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CADUET and ELETRIPTAN HYDROBROMIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CADUET is: CADUET (amlodipine/atorvastatin) is available as tablets of 2.5/10, 2.5/20, 2.5/40, 5/10, 5/20, 5/40, 5/80, 10/10, 10/20, 10/40, and 10/80 mg amlodipine/atorvastatin. Initial dose depends on current antihypertensive and lipid-lowering therapy. Usual starting dose is 5/10 mg orally once daily; titrate at intervals of 2-4 weeks based on blood pressure and LDL-C goals. Maximum daily dose: amlodipine 10 mg; atorvastatin 80 mg.. The standard adult dose of ELETRIPTAN HYDROBROMIDE is: 40 mg orally once, may repeat after 2 hours if headache recurs; maximum 80 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CADUET and ELETRIPTAN HYDROBROMIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CADUET is classified as Category C. FDA Pregnancy Category X. Amlodipine: No evidence of teratogenicity in animal studies, but limited human data; atorvastatin: contraindicated in pregnancy as HMG-CoA reductase inhib. ELETRIPTAN HYDROBROMIDE is classified as Category D/X. Limited human data; animal studies show no teratogenicity at clinically relevant doses. First trimester: risk cannot be excluded; second/third trimester: no known increased risk. A. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.